Researchers have identified a gene associated with 70% of estrogen receptor (ER)-negative breast cancers, reports a study published online July 14 in Nature.
Researchers have identified a gene associated with 70% of estrogen receptor (ER)-negative breast cancers, reports a study published online July 14 in Nature.
Investigators at Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, used a new technique-RNA interference (RNAi)-based loss-of-function screening-to analyze hundreds of genes at a time, seeking the ones that drive tumor formation and growth. When they injected cancerous cells with genetic material that can deactivate genes, they observed that the gene phosphoglycerate dehydrogenase (PHGDH) was significantly more active than normal in 70% of ER-negative tumors, which are difficult to treat because they don’t respond to hormone therapies.
The gene catalyzes production of the amino acid serine. Cancer cells with high PHGDH protein expression have increased serine synthesis; suppressing PHGDH markedly decreases cell proliferation and serine synthesis in cells with elevated PHGDH expression but not in cells without it.
The authors conclude that certain breast cancers depend on PHGDH overexpression to increase serine pathway flux. They assert that their findings demonstrate the usefulness of in vivo negative-selection RNAi screens to identify other potential anticancer targets.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More